Navigation Links
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Date:5/13/2008

slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm. Please dial in or access the website five to 10 minutes prior to the beginning of the call. If you do dial in, please also view the slides via the webcast. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This ann
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
2. XTENT Announces First Quarter 2008 Financial Results
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... , , SILVER SPRING, Md. , Feb. ... approved Xiaflex (collagenase clostridium histolyticum) as the first drug to ... can affect a person,s ability to straighten and properly use ... affects the connective tissue found beneath the skin in the ...
... 2 Vermillion, Inc. (Pink Sheets: VRML) today announced the reappointment ... Company and Eric T. Fung , MD, PhD as Senior Vice ... announced appointment of William C. Wallen , PhD to the Board ... Chair of the Board of Directors. , "Both Dr. Fung and I ...
Cached Medicine Technology:FDA Approves Xiaflex for Debilitating Hand Condition 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 2Vermillion Announces the Reappointment of Officers and Confirmation of Director 3Vermillion Announces the Reappointment of Officers and Confirmation of Director 4
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress ... of gorgeous Quinceanera dresses . , ... Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving ... newly released dresses are made according to the ... vivid. , It is worthy of mention ...
(Date:7/13/2014)... July 13, 2014 Recently, MyDressCity.com, one ... women’s special occasion outfits, has released its new range ... the new products are available at discounted prices. Worldwide ... 2014. , In the company’s online shop, there ... of them are made with great materials. MyDressCity.com’s hot ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... A decreased ability to identify odors might indicate ... while examinations of the eye could indicate the ... in the brain, according to the results of ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... ability to identify odors was significantly associated with ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... Feb. 26 Endo Pharmaceuticals (Nasdaq: ENDP ... to the company,s board of directors. Mr. Montague, ... of Mark IV Industries, retired in July last year. ... highly-engineered systems and components for the transportation, industrial and ...
... after sessions, study finds , , THURSDAY, Feb. 26 (HealthDay ... breast cancer patients, contends a new U.S. study. , ... many women with breast cancer experience, the opportunity to ... of breast cancer is a significant benefit," lead researcher ...
... Laboratories,the newly expanded dermatology division of Valeant Pharmaceuticals,International ... data presentations on Acanya,Gel at the 67th Annual ... place March 6 - 10, 2009, at the ... efficacy and safety of once daily Acanya Gel,(clindamycin ...
... Feb. 26 If you,re looking for an example ... Program, consider Wells Fargo Bank, which has received $25 ... bank has inexplicably withheld tens of thousands of dollars ... Southern California behavioral healthcare treatment center have used to ...
... The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com ... the fourth quarter ended December 31, 2008, compared to $10.7 million ... December 31, 2008, net sales were $20.5 million compared to $28.2 ... , The decrease in net sales for the fourth quarter ...
... All Levels of SocietyWASHINGTON, Feb. 26 A ... percent of colon cancer cases and 38 percent ... preventable through diet, physical activity and weight management. ... reduce the global number of cancer cases.The overall ...
Cached Medicine News:Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 2Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 3Health News:Yoga May Bring Calm to Breast Cancer Treatment 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 3Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 4Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 5Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 2Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 3Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 5Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 6Health News:The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future 7Health News:Report: Many Cancers Could Be Prevented in US 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: